Skip to main content
Premium Trial:

Request an Annual Quote

Greg Lucier

Greg Lucier has become CEO of NuVasive, a medical device company focusing on spine surgery, after serving as the firm's interim CEO since April. He has been a member of NuVasive's board of directors since late 2013 and will continue as the board's chairman.

Until early 2014, Lucier was chairman and CEO of Life Technologies, which was acquired by Thermo Fisher Scientific last year. Previously, he was a corporate officer of General Electric and an executive at GE Medical Systems. Lucier holds a bachelor's degree in engineering from Pennsylvania State University and an MBA from Harvard Business School.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.